Corcept Therapeutics stock tanks on FDA relacorilant setback — what happens next for CORT
NEW YORK, January 1, 2026, 3:46 PM ET — Market closed. Corcept Therapeutics shares ended the last U.S. session down 50.4% at $34.80 after the Food and Drug Administration declined to approve the company’s drug relacorilant for a rare hormonal-disorder-related blood-pressure condition. StockAnalysis